Prolira is all about brain state monitoring in routine hospital care - important to detect and treat acute encephalopathy and delirium.
Delirium (acute brain failure) affects over 3 million hospitalised patients in Europe every year. It is a potentially fatal medical emergency that regularly leads to long-term cognitive impairment (dementia), results in longer hospital admission, and directly contributes to higher healthcare costs. Delirium equals diabetes in societal costs, estimated at €173 billion. The longer a delirium episode lasts, the more damage is done.
To date, delirium is detected too little and too late, as detection is based on subjective and ineffective methods. It is our challenge to solve the unmet clinical need for accurate and safe delirium detection, ànd making the solution fit into routine care.
Prolira, a spin-off from the University Medical Center Utrecht (NL), responds to this market need through the introduction of an innovative, non-invasive medical device for delirium detection. Prolira's EEG-based device consists of a single use electrode patch (the DeltaScan Patch) and a hardware/software module (the DeltaScan Monitor), that analyses brain activity.
DeltaScan is a breakthrough for delirium recognition and treatment. By early detection and more detection, Prolira tackles the problem at the source.
Delirium (acute brain failure) affects over 3 million hospitalised patients in Europe every year. It is a potentially fatal medical emergency that regularly leads to long-term cognitive impairment (dementia), results in longer hospital admission, and directly contributes to higher healthcare costs. Delirium equals diabetes in societal costs, estimated at €173 billion. The longer a delirium episode lasts, the more damage is done.
To date, delirium is detected too little and too late, as detection is based on subjective and ineffective methods. It is our challenge to solve the unmet clinical need for accurate and safe delirium detection, ànd making the solution fit into routine care.
Prolira, a spin-off from the University Medical Center Utrecht (NL), responds to this market need through the introduction of an innovative, non-invasive medical device for delirium detection. Prolira's EEG-based device consists of a single use electrode patch (the DeltaScan Patch) and a hardware/software module (the DeltaScan Monitor), that analyses brain activity.
DeltaScan is a breakthrough for delirium recognition and treatment. By early detection and more detection, Prolira tackles the problem at the source.
Location: Netherlands, Utrecht
Employees: 11-50
Total raised: $5.71M
Founded date: 2015
Investors 2
| Date | Name | Website |
| 14.01.2022 | Holland Ve... | hollandcap... |
| 21.11.2021 | Borski Fun... | borskifund... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.02.2022 | - | $5.71M | - |
Mentions in press and media 2
| Date | Title | Description |
| 15.03.2023 | Prolira secures FDA clearance for its DeltaScan brain state monitor | Prolira says DeltaScan’s display is easy for a clinician to interpret. It shows a positive or negative result for acute encephalopathy. [Image courtesy of Prolira]Prolira (Utrecht, the Netherlands) announced today that the FDA has cleared i... |
| 07.02.2022 | Dutch scaleup Prolira raises €5M to help treat acute encephalopathy and delirium; here’s how | Utrecht-based Prolira, a startup that helps hospital departments improve patient care in cases of acute brain failure (acute encephalopathy and delirium), announced that it has raised €5M in a fresh round of funding. The round was led by Bo... |